EGFR and non-small cell lung carcinoma: After platinum-based chemotherapy, patients with non-small cell lung cancer harboring EGFR Exon20 achieved a risk reduction in terms of their PFS and overall survival with treatment of amivantamab in the CHRYSALIS trial compared with LC-SCRUM-Asia patients who were treated with docetaxel, classic TKIs, or immunotherapy.